PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUICHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY WASHINGTON, DC 20510-6275

BRUCE A. COHEN, Chief Counsel and Staff Director KOLAN L. DAVIS, Republican Chief Counsel and Staff Director

May 4, 2011

Via Electronic Transmission

John R. Seffrin Chief Executive Officer American Cancer Society, Inc. 250 Williams Street Atlanta, GA 30303

Dear Mr. Seffrin:

In December 2009, I asked for an accounting of industry funding that the American Cancer Society, Inc. (ACS) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing. The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on ACS's website.

As of the date of this letter, it appears that no additional information regarding your organization's industry funding has been posted on the ACS's website. If ACS is currently

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

taking steps to enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. If not, please explain why your organization does not support the disclosure of funding it receives from pharmaceutical and device companies.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with:...physician groups and other prescribers...patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,

Charles E. Grassley Ranking Member

Chuck Gradey

Attachments

³ *Id*.

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

Attachment



Sheffield Hale Chief Counsel

January 15, 2010

Senator Charles E. Grassley United States Senate Committee on Finance Washington, D.C. 20510-6200

ATTN: Paul Thacker and Brian Downey

Dear Senator Grassley:

This letter responds to the Senate Finance Committee's December 7, 2009, request for information on funding received by the American Cancer Society, Inc., (the "Society") from pharmaceutical companies, medical device companies, foundations established by these companies, and the insurance industry ("PMI Funders"). As will be explained below, the Society receives less than 1.5 percent of its total income from PMI Funders.

The Society holds itself to the highest standards of transparency and public accountability in its continuing quest to save lives by eliminating cancer as a major health problem. At the start of this new year, it is worth remembering that in 2010, nearly 600,000 Americans are expected to die of cancer. That is more than 1,500 deaths a day. Furthermore, an estimated 1.5 million Americans will receive a diagnosis of cancer during the same period. That means more than 4,500 Americans will hear their doctors say, "You have cancer," each and every day this year. These statistics underscore the importance of the battle against cancer. As the nation's largest voluntary health organization, the Society knows that it cannot fight this disease without maintaining the highest standards of stewardship that are essential to give Americans confidence in the integrity of our organization.

The Society will celebrate its 100th birthday in 2013, and that is, in part, due to its long and successful commitment to public accountability and responsible stewardship of donor resources. Given this organizational ethic, the Society is highly responsive to current governmental and public concerns about appropriate use of tax-deductible contributions. Accordingly, the Society over time has adopted a series of enhancements to its Board governance and operational policies and procedures intended to reflect nonprofit sector best practices and new transparency

guidelines for charitable organizations. Below, in response to the Committee's request for information, we explain these in detail and also discuss the attached accounting of industry funding.

At the outset, however, we would like to provide information that we believe provides context responsive to the Committee's concerns about the relationship between our organization and PMI Funders. Specifically, we will discuss sources of the Society's funding and governance practices that safeguard individual donor dollars.

Financial Support of the American Cancer Society

Donor confidence is essential to the Society's success. The overwhelming majority of the Society's financial support comes directly from voluntary contributions from the public at large. Here are some recent statistics:

- In 2009, 6.9 million donors made more than 9 million gifts to the Society, with an average gift size of \$67, excluding planned gifts. More than 6.6 million of those 6.9 million donors (95.7 percent) were individuals, approximately 325,000 donors were corporations, and approximately 6,000 were charitable foundations.
- The Society raised approximately 59 percent of its 2009 revenue through community-based special events by leveraging the talents and commitment of individual volunteers and participants, including:
 - 5,034 American Cancer Society Relay For Life[®] events, which raised more than \$386 million, with an estimated 3.5 million participants including more than 700,000 cancer survivors.
 - More than 140 Making Strides Against Breast Cancer[®] events which raised more than \$50 million, with an estimated 600,000 participants and 55,000 survivors.

Between 2006 and 2009, less than half of 1 percent of all corporate donors to the Society were PMI Funders, and their contributions accounted for less than 1.5 percent of the Society's total income. The Society accepts this support according to the specific policies and procedures described below that apply to all corporate contributions to ensure that funding will be used to pursue the Society's lifesaving mission.

_

In describing financial support, we define the Society broadly to include ACS, Inc. and its related organizations. ACS, Inc., is a national organization with affiliated Divisions, a foundation, and an affiliated 501(c)(4) organization. To provide complete transparency, we have included industry funding provided not only to ACS, Inc., as you requested, but also industry funding provided to organizations affiliated with ACS, Inc. They include: The American Cancer Society Foundation, American Cancer Society California Division, Inc., American Cancer Society Eastern Division, Inc., American Cancer Society Florida/Puerto Rico Division, Inc., American Cancer Society Great Lakes Division, Inc., American Cancer Society High Plains Division, Inc., American Cancer Society High Plains Division, Inc., American Cancer Society Mid-South Division, Inc., American Cancer Society Midwest Division, Inc., American Cancer Society New England Division, Inc., American Cancer Society Ohio Division, Inc., American Cancer Society Pennsylvania Division, Inc., American Cancer Society South Atlantic Division, Inc., and American Cancer Society Cancer Action Network, Inc.

It is important to note that not one of the nearly 325,000 corporate donors is a tobacco company. The Society has an absolute prohibition on accepting support from the tobacco industry. This prohibition is aligned with the Society's mission: since the first Surgeon General's report on smoking and health in 1964, there have been more than 12 million premature deaths attributed to smoking in the United States.

Governance Practices

The Society is committed to transparency and accountability as a means to safeguard donor dollars. To that end, the Society regularly monitors and implements, where appropriate, guidance offered by nonprofit associations, such as Independent Sector, and by the Internal Revenue Service. The Society currently follows the practices reflected in Part VI of Form 990, the IRS discussion of Governance and Related Topics for 501(c)(3) Organizations, and the Principles for Good Governance and Ethical Practice set forth by the Panel on the Nonprofit Sector.

For example, the Society's Code of Ethics (which is attached under Exhibit B) provides for annual disclosure of financial interests in any business that engages in financial transactions with the Society. The Society has also adopted a document retention policy and provides protection for whistleblowers. In addition, the Society makes public on its Web site its governing documents, its Form 990, and its financial statements. The Society's Audit Committee, which is responsible for reviewing conflict of interest issues, is composed entirely of independent directors. Furthermore, the Society's Board of Directors is composed entirely of independent volunteer citizen members and is organized to facilitate active Board oversight of the Society's operations and finances.

Accounting of Industry Funding

The Committee has requested an accounting of funding provided to the Society by pharmaceutical companies, medical device companies, foundations established by these companies, and the insurance industry between 2006 and 2009.

The Society received nearly \$4 billion in total income between 2006 and 2009, of which \$58,227,286 was contributed by PMI Funders, representing less than 1.5 percent of the Society's total income over this period.

Under Exhibit A, we have attached a list of the PMI Funders that have supported the Society and its related organizations over the past four years, along with the amount, date, and purpose of each contribution. As specified in your request, in compiling this data, we defined the term "industry funding" to mean any transfer of value, including but not limited to grants, donations, and sponsorship for meetings or programs, etc. We have included aggregate contributions for those companies with less than \$20,000 in donations on page 7 of Exhibit A under Other Pharmaceutical, Medical Device Companies, Foundations, and Insurance Companies². We believe this data materially satisfies the Committee's request.

² We interpreted your request for insurance companies to mean all types of insurance companies, including health insurance, life insurance, property, and casualty insurance companies.

Policies

The Committee has asked a number of questions about the Society's policies with respect to industry funding, transparency, and outside income. Below, we have reproduced your questions and provided our responses.

Industry Funding

- Please describe the policies for accepting industry funding and whether or not the American Cancer Society allows companies to place restrictions or provide guidance on how funding will be spent.
- 2. If the Society allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company, and restriction placed on funding.

The Society's long-standing position on acceptance of industry funding is set forth in its Policy on Corporate Relationships, which is attached under Exhibit C. Consistent with long-standing practice, the Society solicits and accepts restricted contributions only for purposes that meet its specified mission delivery program guidelines or priorities. The Society is an accredited member in good standing of the National Health Council because its policies and practices meet the National Health Council Standards of Excellence. These standards demand the highest level of accountability and ethical practice to assure the public that the organizations meeting these standards are worthy of support. For a detailed listing of the National Health Council's Standards of Excellence for voluntary health agencies, please visit www.nationalhealthcouncil.org/forms/soe.pdf.

As shown in the data provided of industry funding under Exhibit A, approximately 60 percent of contributions by PMI Funders are accepted subject to restrictions on use. Detail with respect to each transfer (year of transfer, name of company, and restriction placed on funding) is included under Exhibit A. Below we explain each of the listed restrictions on use, which fall into the following twelve categories:

- Breast cancer general. Restricted donations in this category are used to support the Society's work to eradicate breast cancer, including research, patient services, and prevention and early detection programs.
- Camps for children with cancer. Restricted donations in this category are used to support
 the Society's free summer camps for children with cancer. Staffed by pediatric oncologists
 and nurses, these camps provide a place for children in treatment or remission to become kids
 again through the summer camp experience.
- Cancer prevention and early detection. Restricted donations in this category are used to
 support the Society's cancer prevention and early detection efforts. The Society's prevention
 programs focus primarily on: tobacco control; the relationship between diet, physical
 activity, and cancer; promoting coordinated school health programs; and reducing the risk of
 skin cancer. Programs are designed to help adults and children make health-enhancing
 decisions and act on them. The Society also seeks, through the dissemination of its early

- cancer detection guidelines and its cancer detection and advocacy programs, to ensure that cancer is diagnosed at the earliest possible stage, when there is the greatest chance of successful treatment.
- Geographic. Restricted donations in this category are used to support the Society's work in specific geographic areas.
- Hope Lodge[®]. Restricted donations in this category are used to support the Society's Hope Lodge facilities, which provide a free, supportive place to call "home" for cancer patients and their families during treatment. Getting the right care sometimes means that cancer patients must travel far from home, often to a cancer treatment facility in another city, adding the additional burden of transportation, hotel, and meal expenses. Many cancer patients are forced to go into debt, or take their second or third choice of treatment simply because the cost of travel is too great. Currently, there are 29 Hope Lodge locations throughout the United States.
- Nutrition and physical activity programs. Restricted donations in this category are used to
 support the Society's nutrition and physical activity programs, including research and
 education. For example, every five years the Society publishes nutrition and physical activity
 guidelines, which are developed by a national panel of experts in cancer research, prevention,
 epidemiology, public health, and policy, and as such, they represent the most current
 scientific evidence related to dietary and activity patterns and cancer risk.
- Patient Navigation Programs. Restricted donations in this category are used to support the
 Society's Patient Navigator Programs, which provide guidance for cancer patients, their
 families, and caregivers to help them through the cancer treatment experience, with a focus
 on identifying and eliminating barriers to cancer care for the medically underserved. Patient
 navigators serve as personal guides by providing information, day-to-day help, and emotional
 support.
- Patient services. Restricted donations in this category are used to support the Society's
 patient services programs, which provide a wide range of emotional and practical support for
 patients, their families, their caregivers, and their communities from the time of diagnosis to
 the end of the cancer experience. For example, the Road to Recovery® program provides
 transportation to and from treatment for people who have cancer and do not have a ride or are
 unable to drive themselves.
- Scientific research. Restricted donations in this category are used to support the Society's
 research program, which includes both external grants and in-house cancer research. With its
 external grants, the Society which is the nation's largest private, not-for-profit source of
 funds for scientists studying cancer focuses its funding on investigator-initiated, peerreviewed proposals. The success of the Society's grant program is perhaps best illustrated by
 the fact that 44 grant recipients have gone on to win the Nobel Prize. The Society also
 conducts in-house cancer research in a wide variety of areas, including epidemiology and
 behavioral and psychosocial research.
- Tobacco control. Restricted donations in this category are used to support the Society's
 wide-ranging tobacco control efforts, which include everything from research and education
 to policy work and direct patient services.

- Youth cancer survivor scholarships. Restricted donations in this category are used to support the Society's youth cancer survivor college scholarship program, which is a scholarship opportunity exclusively for students with a history of cancer. The program provides young cancer patients/survivors assistance in pursuing higher education from an accredited school.
- Other program restrictions. Restricted donations in this category, approximately \$782,638
 (1% of the total), are used to support miscellaneous Society activities that do not fit into any
 of the other categories such as our health insurance assistance service, clinical trials matching
 service, and pain awareness.

Transparency

3) Please explain what policies, if any, that the American Cancer Society plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.

As discussed above, the Society has worked hard to maintain the public trust by exercising responsible stewardship over contributions and by adopting governance practices that encourage public confidence in charitable organizations. The Society either meets or exceeds the standards established by numerous charitable "watchdog" agencies. The Society holds the Better Business Bureau national charity seal of approval and is accredited by the Bureau's Wise Giving Alliance for satisfying Standards for Charitable Accountability, which are available at www.bbb.org/us/Charity-Standards. The seal provides the public with a clear, concise, and easily recognizable symbol that the subject national charity adheres to the Alliance's strong and comprehensive standards.

In addition, as noted above, the Society meets the National Health Council Standards of Excellence, which signal that the Society satisfies the highest levels of accountability and ethical practice and is worthy of support. Additionally, the Society's Board Audit Committee and its Governance Committee are both charged with the continuing responsibility to consider additional policies and emerging procedures as may prove necessary to protect against conflict of interest and inappropriate influence. The Society will continue to monitor the evolution of best practices in governance in the nonprofit sector and will adopt practices that are appropriate for the Society and that foster continued public confidence in its independence.

Outside Income

- Please explain your policies on disclosure of outside income by your top executives and board members.
- Please provide the disclosures of outside income filed with your organization by your top executives and board members.

The Society requires all employees and directors to comply with its Code of Ethics (Exhibit B), including the Conflict of Interest Policy. The policy is designed to ensure that the Society benefits from the undivided loyalty of its staff and directors, while recognizing that these individuals will have relationships and obligations outside the Society. In order to prevent any

such relationships or obligations from influencing their decisions at the Society, the policy requires all Board members and staff to disclose, at least annually, any position that would result in a conflict of interest or the appearance of a conflict of interest. Hence, all directors and executives must disclose sources of income that would interfere with their duties to the Society. This information is used by the Board Audit Committee, as well as by the Office of Chief Counsel, to identify circumstances where an individual decision maker should be recused from the Society's decision-making process. Thus, this practice appropriately balances the Society's interests with the outside commitments of its directors and staff.

Staff who earn outside income, such as honoraria, fees, or commissions while working on Society-compensated time are, of course, required to turn that income over to the Society. The Society has not adopted a formal policy requiring disclosure of outside income by its top executives and Board members. Instead, it has relied on its Conflict of Interest Policy, which mandates disclosure of the relationships that may create conflicts of interests rather than on disclosure of all outside income. The policy has been reviewed and approved by the Society's Board of Directors, which retains ultimate responsibility for ensuring responsible stewardship of Society funds.

The Board takes its responsibility for ensuring organizational transparency and accountability seriously and has created a Governance Committee to consider whether the Society's governance procedures are consistent with evolving nonprofit best practices. In light of emerging best practices, the Board's Governance Committee will be considering additional protections, including whether the Society should adopt a formal policy on disclosure from its Board members of outside income and stock ownership from PMI Funders.

In direct response to your inquiry, the Society's Chief Executive Officer solicited detailed information from all of the Society's employed "Disqualified Persons" and its key medical and scientific executives with respect to sources of outside income and stock ownership information (other than diversified independently managed investment vehicles such as mutual funds) with and from PMI Funders. Only one income relationship between a PMI Funder and any of those individuals was reported. This individual, who joined the Society in January 1, 2009, had a two year pre-existing relationship with a biotech company where he serves as a scientific advisor with a yearly stipend of \$48,000.

Only one individual reported stock ownership in PMI Funders in excess of \$10,000. The individual has holdings in two large publicly traded companies with a current value between \$10,000 and \$40,000. The Society has adopted a policy to provide that all employed Disqualified Persons and medical and scientific executives must receive approval from the Chief Executive Officer, Chief Medical Officer, and Chief Counsel prior to entering into any income relationship with a third party and to prohibit any compensated relationship with a PMI Funder. The Society will continue to annually solicit detailed information on outside income and stock ownership from these executives.

7

³ As defined in IRC 26 U.S.C. § 4958(f)(1).

The American Cancer Society has never taken for granted the trust and generous support of the American public – trust that it has earned and received for nearly a century. It is with that trust in mind that the Society routinely evaluates emerging standards and best practices in the areas of nonprofit governance and public accountability. Our organization remains committed to playing a leadership role in the independent, nonprofit sector and in our civil society. We hope these responses have satisfied the Committee's questions.

Sincerely,

F. Sheffield Hale

Enclosures

Exhibits

- A. Funding from pharmaceutical companies, medical device companies, foundations established by these companies, and the insurance industry
- B. Code of Ethics and Conflict of Interest Policy, American Cancer Society, Inc., and Its Affiliated Entities
- C. Policy on Corporate Relationships

Exhibit A

COMPANY NAME	DONATION RESTRICTION	2006	2007	2008	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Grand Total
ABBOTT LABORATORIES	BREAST CANCER - GENERAL	251	3	1,4/1		76/1
	GEOGRAPHIC	1,874	006	6,650	1,930	11,354
	HOPE LODGE		2,500	3,162	1,594	10,256
	OTHER PROGRAM RESTRICTIONS			1,000		1,000
	SCIENTIFIC RESEARCH			20		20
	UNRESTRICTED DONATIONS	223,083	277,837	506,933	51,263	1,059,116
ABBOTT LABORATORIES Total		225,208	284,267	519,265	54,788	1,083,528
						-
ACTELION PHARMACEUTICALS	BREAST CANCER - GENERAL		2,650	2,000		069.7
AND IN THE PROPERTY OF THE PRO	UNRESTRICTED DONATIONS		10,000	13,532		34 183
ACTELION PHARMACEUTICALS Total			12,830	700'01		201,102
ACUITY INSURANCE	UNRESTRICTED DONATIONS		23,000	40,000	65,000	128,000
AEGON	HOPE LODGE	20,000				20,000
AETNA	BREAST CANCER - GENERAL	17.960	10.210	35.480	9.739	73.390
	CAMPS FOR CHILDREN WITH CANCER			42	25.042	25.084
	GEOGRAPHIC	1,607		8,000		7,807
	HOPE LODGE	740	1,889	292	98	2,757
	SCIENTIFIC RESEARCH	168	234	2,503	32	2,836
	TOBACCO CONTROL				2,000	2,000
	UNRESTRICTED DONATIONS	212,557	172,890	166,109	41,031	592,586
AETNA Total		233,031	185,022	210,426	77,880	706,360
ALIANZ	LINDESTRICTED DONATIONS		10 000	20.000	24.000	54.000
דרונוזאד				The second		
ALLSTATE FOUNDATION	BREAST CANCER - GENERAL		2,000	3,000	200	5,500
	CAMPS FOR CHILDREN WITH CANCER	1		440.77	1,000	1,000
THE RESIDENCE OF THE PARTY OF T	UNRESTRICTED DONATIONS	8 5	27,550	14,250	00000	86,850
ALLSTATE FOUNDATION Total		8	000'67	003,11	200,02	200
ALLSTATE INSURANCE COMPANY	BREAST CANCER - GENERAL	909	3,910	1,275	1,050	6,840
	CAMPS FOR CHILDREN WITH CANCER	631	649	365	88	1,703
	PATIENT NAVIGATION PROGRAMS			2	100	100
	UNRESTRICTED DONATIONS	69,919	61,940	80,388	95,952	308,198
ALLSTATE INSURANCE COMPANY Total		71,155	66,499	82,048	97,159	316,861
AMEDICAN SAMILY INSTIDANCE	BREAST CANCER - GENERAL	525		25	275	825
	GEOGRAPHIC	42,000		28,000	28,000	98,000
	HOPE LODGE	510	300	20 746	92 863	472 608
AMERICAN FAMILY INSURANCE Total	UNRESTRICTED DONATIONS	76,131	70,335	64,741	61,127	272,333
AMERICAN FAMILY LIFE ASSURANCE COMPANY OF COLUMBUS (AFLAC)	BREAST CANCER - GENERAL	1,000	120	2,500	2,000	5,620
	UNRESTRICTED DONATIONS	45,094	21,689	1,000	27,218	94,979
AMERICAN FAMILY LIFE ASSURANCE COMPANY OF COLUMBUS (AFLAC) Total		46,094	21,789	3,500	29,216	100,599
AMERICAN INTERNATIONAL GROUP (AIG)	BREAST CANCER - GENERAL				125	125
	SCIENTIFIC RESEARCH			100		100
AMERICAN INTERNATIONAL GROUP (AIG) Total	UNRESTRICTED DONATIONS	25,800		6,100	14,975	45,875
AMERICAN PHARMACEUTICAL PARTNERS	BREAST CANCER - GENERAL	125				125
	PATIENT SERVICES	1,000	4 636	8.028	775	21.734
AMERICAN PHARMACEUTICAL PARTNERS TOTAL		11,422	4,636	6,026	277	22,859
AMGEN	BREAST CANCER - GENERAL	4,290	3,716	5,825	098	14,781
	CAMPS FOR CHILDREN WITH CANCER		200	2.500		2.700

COMPANYNAME	STRICTION	2006	-	15 500	S) SOME MONEY	40 500
	GEOGRAPHIC	000'01	3,000	5.200	100	8,300
	OTHER PROCESS M PECTRICALONS		2000	200		5.000
	DANIEL PROGRAM REGINGING	7007	38,000	21 500	102 200	160.400
	PATIENT DESEMBLE	3	300	200114	200	300
	LINDESTRUCTED DONATIONS	185 921	100 776	103 294	143.138	533.129
AMORA MACHA	OWEST MOTES DOWN TO A	200 911	163.992	153.819	246.388	785,110
DINICEN LOISI						2
ASSURANT	BREAST CANCER - GENERAL	155	450	1,050	485	2,140
	GEOGRAPHIC	2,500	2,500	2,500	2,500	10,000
	UNRESTRICTED DONATIONS	12,497	15,778	10,413	10,911	49,599
ASSURANT Total		15,152	18,728	13,963	13,896	61,739
TO ALTHOUGH TO ALT	INCOME TO	74 400	AE 037	28 600	38 010	207 547
ASIRACENECA	CAMPS COD CUI DOEN MITH CANCED	2014	2000	200'07	01000	2,000
	CANCER PREVENTION & PARI Y DETECTION	250	20013			250
	GEOGRAPHIC	3,000			10	3,000
	HOPE LODGE	7,000,000	633	14,750	5,000	7,020,383
	OTHER PROGRAM RESTRICTIONS	16,000	12,500	10,000	3,000	41,500
	PATIENT NAVIGATION PROGRAMS		2,001,500	3,005,000	1,023,700	6,030,200
	PATIENT SERVICES	2007		200	200	1,900
	SCIENTIFIC RESEARCH		140,000			140,000
	TOBACCO CONTROL	000	037 027	2,500	5,000	006,7
The state of the s	UNRESTRICTED DONATIONS	000,082	061,871	3 2 4 0 4 7 8	1 186 180	14 161 076
ASTRAZENECA Total		000,4/6,1	2,400,020	0,410,410	201,001,1	201011
AURORA IMAGING TECHNOLOGY	BREAST CANCER - GENERAL		25,000	25,775	25,638	76,413
	UNRESTRICTED DONATIONS	200	4 III SHOW			200
AURORA IMAGING TECHNOLOGY Total		200	25,000	25,775	25,638	76,913
AVIIVA	HOPETODGE		25,000	25,000	25,000	75,000
COMM						
BAXTER INTERNATIONAL	BREAST CANCER - GENERAL		12,400		0.00	12,400
	GEOGRAPHIC	190	000		nen's	3,800
	LINBESTRICTED DONATIONS	11.600	27,805	3,480	18,345	61,230
BAXTER INTERNATIONAL Total		11,750	42,105	3,480	21,395	78,730
	The second secon		000	000	20,00	800 91
BAXTER INTERNATIONAL FOUNDATION	BREAST CANCER - GENERAL	USB'L	200	800'*	7/6/7	200
	UNRESTRICTED DONATIONS	32,265	35,139	43,227	37,855	148,486
BAXTER INTERNATIONAL FOUNDATION Total		34,195	42,071	48,116	40,332	164,714
BAYER	BREAST CANCER - GENERAL				209	209
	CAMPS FOR CHILDREN WITH CANCER				100	100
	CANCER PREVENTION & EARLY DETECTION	150,000	2002	1 700		2,400
	PALIEN SERVICES	260	24 000	5,050		29.300
BAYER Total	ONNEST RICIED CONTINUES	150,250	24,700	6,750	309	182,009
				5		
BECKMAN COULTER	BREAST CANCER - GENERAL	687	2,830	000 30	00030	3,517
	YOUTH CANCER SURVIVOR SCHOLARSHIPS	10,000	25,000	20,000	20,000	103 930
BECKWAN COLITER Total	UNRESTRICTED DONATIONS	18,671	62,510	66,127	45,139	192,447
	THE RESERVE OF THE PARTY OF THE					
BECTON, DICKINSON AND COMPANY	BREAST CANCER - GENERAL	1,255	2,105	2,175	1,635	7,170
	HOPE LODGE	10,000	20 525	63.873	65.492	160,397
BECTON, DICKINSON AND COMPANY Total	ON THE PROPERTY OF THE PROPERT	12,763	22,630	66,048	67,127	168,567
						100
BIOGEN IDEC	UNRESTRICTED DONATIONS	11,201	11,366	1,409	1,125	75,101

BLUE CROSS BLUE SHIELD PREAST CANCER - CENERAL BLUE CROSS BLUE SHIELD PREAST CANCER - CENERAL BLUE CROSS BLUE SHIELD CANCER PREVENTION & EARLY DETECTION CANCER PREVENTION & EARLY DETECTION CANCER PREVENTION & EARLY DETECTION BLUE CROSS BLUE SHIELD Total PROPER TOTAL AND PROGRAMS BLUE CROSS BLUE SHIELD FOUNDATION PROPERTY CREETED DONATIONS BLUE CROSS BLUE SHIELD FOUNDATION TOTAL PROPERTY CREETED DONATIONS BLUE CROSS BLUE SHIELD FOUNDATION TOTAL PRESTINCTED DONATIONS BLUE CROSS BLUE SHIELD FOUNDATION TOTAL PATIENT WANGATION FROGRAMS BLUE CROSS BLUE SHIELD FOUNDATION TOTAL PATIENT SERVICES BOSTON SCIENTIFIC CORPORATION TOTAL BRESTOLANCER - GENERAL BOSTON SCIENTIFIC CORPORATION TOTAL BRESTOLANCER - GENERAL BOSTON SCIENTIFIC CORPORATION TOTAL BREAST CANCER - GENERAL CALGENE HORE LODGE PATIENT SERVICES PATIENT SERVICES CALGENE PATIENT SERVICES CARDINAL HEALTH TOTAL OTHER PROGRAMS ESTICATED DONATIONS CARDINAL HEALTH TOTAL OTHER PROGRAMS ESTICATED DONATIONS CARDINAL HEALTH TOTAL OTHER PROGRAMS ESTICATED DONATIONS	GENERAL. ION & EARLY DETECTION ON PROGRAMS RCH NL IRCH NL IRCH ON PROGRAMS	110,300 7,000 35,000 56,000 56,000 11,500 11,500 6,670 9,170 5,100 5,100 5,100 11,500 11,500 11,500 11,500 11,500 11,500 11,500 5,100 5,100 5,100 5,100 11,500	33,334 84,305 2,500 10,000 431,575 573,454 150,000 150,000 12,750 16,382 16,382 16,382 16,382 16,382 16,382	33,333 144,048 5,000 238,000 1,022,087 550,000	33,333 57,547 51,000 100 25,000 403,560 540,581 120,000 120,000 12,000 12,000	386,200 12,000 37,500 37,500 37,500 1,844,001 1,844,021 2,721,260 560,000 120,000 12,500 2,500 13,846 32,916 13,386
ROSS BLUE SHIELD ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION N SCIENTIFIC CORPORATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB Total AL HEALTH Total COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total	GENERAL ION & EARLY DETECTION ON PROGRAMS RCH IRVIVOR SCHOLARSHIPS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS	110,300 7,000 3,000 56,000 56,000 11,500 11,500 6,670 9,170 5,100 5,100 5,100 70,789	2,500 2,500 10,000 45,000 11,000 150,000 150,000 150,000 15,382 16,382 16,382 16,382 16,382	5,000 238,000 1,022,087 550,000 550,000	57,547 3,384 51,000 100 25,000 403,580 540,581 120,000 12,000 12,000 12,775 2,775	396,200 12,000 37,500 345,000 1,844,021 2,721,260 550,000 150,000 150,000 150,000 150,000 150,000 150,000 150,000 13,916 13,966
	GENERAL ION & EARLY DETECTION ON PROGRAMS RCH IL IRVIVOR SCHOLARSHIPS ON PROGRAMS ON PROGRAMS ONATIONS ONATIONS ONATIONS ONATIONS ONATIONS ONATIONS	110,300 35,000 35,000 56,000 56,000 11,500 11,500 6,670 9,170 5,100 5,100 5,100 11,500 11,500 11,500 11,500 11,500 11,500 11,500 5,100 5,100 5,100 5,100	2,500 2,500 10,000 431,575 573,464 150,000 12,750 18,382 16,382 16,382 16,382 16,382 16,382 16,382	5,000 5,000 635,039 1,022,087 550,000 550,000	3,384 51,000 100 25,000 403,580 540,581 120,000 120,000 12,776 2,776	384,000 17,500 37,500 37,500 174,000 35,000 1,844,021 2,721,260 560,000 120,000 120,000 150,000 150,000 13,916 13,396
ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB AL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH COR ORTHO BIOTECH COR ORTHO BIOTECH Total	ON & EARLY DETECTION ON PROGRAMS RCH ON PROGRAMS ON PROGRAMS INATIONS	7,000 35,000 3,000 56,000 56,000 11,500 11,500 8,670 9,170 5,100 5,100 5,100 501,500 70,789	2,500 74 46,000 10,000 431,576 573,464 150,000 150,000 12,750 16,382 16,382 16,382 16,382 16,382 16,382	5,000 1,022,087 1,022,087 560,000	3,384 51,000 100 25,000 403,580 540,581 120,000 120,000 12,000 12,775 2,775 2,775	345,000 345,000 345,000 35,000 1,844,021 2,721,260 550,000 150,000 120,000 820,000 820,000 30,416 32,916
ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB Total AL HEALTH COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total	ON PROGRAMS RCH JECH JEVIVOR SCHOLARSHIPS INATIONS	35,000 56,000 56,000 11,500 11,500 2,500 6,170 5,100 5,100 5,100 5,100 5,100 5,100 5,100 70,789	74 45,000 10,000 431,575 673,454 150,000 150,000 11,750 16,382 16,382 16,382 16,382 16,382	238,000 635,039 1,022,087 550,000	3,384 51,000 100 25,000 403,580 540,581 120,000 12,000 12,000 12,775 2,775	50,450 50,450 50,450 50,450 50,450 50,450 50,450 50,450 50,450 50,450 50,450 50,450 50,450
ROSS BLUE SHIELD Total ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION INGER INGELHEIM PHARMACEUTICAL INGER INGELHEIM PHARMACEUTICAL IN SCIENTIFIC CORPORATION INGER INGELHEIM PHARMACEUTICAL IN SCIENTIFIC CORPORATION INGER INGELHEIM PHARMACEUTICAL INGER INGELHEIM PHARMACEUTICAL INGER INGELHEIM PHARMACEUTICAL INGER INGELHEIM PHARMACEUTICAL INGEL INGELHEIM PHARMACEUTICAL INGEL I	ON PROGRAMS RCH JECH JEVIVOR SCHOLARSHIPS MATIONS	56,000 373,828 585,128 5,100 5,100 5,100 5,100 5,100 5,100 5,100 70,789	74 45,000 10,000 431,575 573,454 150,000 12,750 18,382 16,382 16,382 16,382 16,382 16,382	238,000 635,039 1,022,087 550,000	51,000 100 100 403,580 540,581 120,000 12,000 12,000 12,000 2,775 2,776	345,000 35,000 1744,021 2,721,260 150,000 150,000 150,000 150,000 120,000 820,000 820,000 30,416 32,916
ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB Total AL HEALTH AL HEALTH COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total	RCH INATIONS	373,828 585,128 11,500 11,500 6,670 9,170 5,100 5,100 5,100 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1	74 45,000 10,000 431,575 573,454 150,000 12,750 16,382 16,382 16,382 16,382 16,382	635,039 1,022,087 560,000 550,000	100 25,000 403,500 540,591 120,000 12,000 12,000 2,775 2,776	174 45,000 345,000 1,844,021 2,721,260 150,000 150,000 120,000 820,000 820,000 2,500 32,816 13,386
ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BL	NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS	373,828 585,128 11,500 2,500 6,670 9,170 5,100 5,100 501,500 70,789	16,000 45,000 431,575 573,454 150,000 150,000 12,750 16,382 16,382 16,382 16,382 16,382	635,039 1,022,087 560,000 550,000	25,000 403,580 540,581 120,000 120,000 12,000 2,775 2,775	45,000 1,844,021 2,721,260 550,000 150,000 120,000 820,000 820,000 820,000 30,416 32,916
ROSS BLUE SHIELD Total ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION Total N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB TOTAL VE VE VE VE VE COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total	NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS NATIONS	373,828 585,128 11,500 2,500 6,870 9,170 5,100 391,330 501,500 70,789	10,000 431,575 573,464 150,000 12,750 18,382 16,382 16,382 16,382 16,382	635,039 1,022,087 550,000 550,000	25,000 403,580 540,581 120,000 12,000 12,000 2,775 2,775	35,000 1,844,021 2,721,260 550,000 120,000 820,000 820,000 820,000 30,416 32,916
ROSS BLUE SHIELD Total ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION N SCIENTIFIC CORPORATION N SCIENTIFI	ON PROGRAMS INATIONS INATIONS GENERAL GENERAL	373,828 585,128 11,500 2,500 6,670 9,170 5,100 5,100 5,100 1391,330 501,500 70,789	431,575 673,464 150,000 150,000 12,750 16,382 16,382 16,382 16,382	635,039 1,022,087 550,000 550,000	403,580 540,591 120,000 12,000 12,000 2,775 2,776	2,721,280 2,721,280 550,000 150,000 820,000 820,000 50,450 30,416 32,916
ROSS BLUE SHIELD Total ROSS BLUE SHIELD TOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB Total AL HEALTH Total COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total	ON PROGRAMS INATIONS INATIONS GENERAL	11,500 11,500 1,500 1,100 9,170 5,100 391,330 501,500 70,788	150,000 150,000 150,000 16,382 16,382 16,382 16,382	950,000	120,000 120,000 12,000 12,000 2,775 2,776	2,721,280 560,000 150,000 820,000 820,000 50,450 30,416 32,916
ROSS BLUE SHIELD FOUNDATION ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL IN SCIENTIFIC CORPORATION IN SCIENTIFIC CORPORATION Total IL-MYERS SQUIBB IL-MYER	ON PROGRAMS INATIONS INATIONS GENERAL	11,500 2,500 6,670 9,170 5,100 391,330 501,500 70,788	150,000 150,000 12,750 16,382 16,382 16,382 16,382	550,000	120,000 120,000 12,000 12,000 2,775 2,776	550,000 150,000 120,000 820,000 50,450 30,416 32,916 13,396
ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL IN SCIENTIFIC CORPORATION IN SCIENTIFIC CORPORATION Total IL-MYERS SQUIBB IL-	ON PROGRAMS INATIONS INATIONS GENERAL	11,500 2,500 6,670 9,170 5,100 391,330 501,500 70,788	150,000 150,000 12,750 16,382 16,382 16,382 51,000	250,000	120,000 120,000 12,000 12,000 2,775 2,776	150,000 120,000 820,000 50,450 30,416 32,916 13,396
ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB Total AL HEALTH AL HEALTH COR ORTHO BIOTECH COR ORTHO BIOTECH Total	NATIONS SENERAL GENERAL	11,500 2,500 8,670 9,170 5,100 391,330 0,500 70,789	150,000 12,750 16,382 16,382 3,971 51,000	250,000	120,000 120,000 12,000 12,000 2,775 2,775	2,500 32,416 32,416 32,916 13,396
ROSS BLUE SHIELD FOUNDATION Total INGER INGELHEIM PHARMACEUTICAL N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB AL HEALTH AL HEALTH COR ORTHO BIOTECH	NATIONS GENERAL GENERAL	11,500 2,500 8,670 9,170 5,100 391,330 501,500 70,788	150,000 12,750 16,382 16,382 3,971 5,1,000	250,000	120,000 12,000 2,775 2,775	50,450 2,500 30,416 32,916
N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB Total L-MYERS SQUIBB Total AL HEALTH AL HEALTH COR ORTHO BIOTECH COR ORTHO	NATIONS GENERAL GENERAL	11,500 2,500 8,670 9,170 5,100 391,330 501,500 70,788	12,750 16,382 16,382 16,382 5,1000		12,000 2,775 2,776	2,500 2,500 30,416 32,916
N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB Total WE VE AL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total	GENERAL.	2,500 6,670 9,170 5,100 391,330 501,500 70,788	16,382 16,382 3,971 51,000	14,200	2,775	2,500 30,416 32,916 13,396
N SCIENTIFIC CORPORATION N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MY	GENERAL GENERAL	2,500 6,870 9,170 5,100 391,330 501,500 700 70,769	16,382 16,382 3,971 51,000		2,775	2,500 30,416 32,916 13,396
N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB L-MYERS SQUIBB VE VE VE Total IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total	GENERAL	5,100 391,330 501,500 707	16,382 16,382 3,971 51,000		2,775	32,916 13,396
N SCIENTIFIC CORPORATION Total L-MYERS SQUIBB Total VE IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOT	GENERAL.	5,100 391,330 501,500 700 700 707	3,971	4,589	2,170	13,396
L-MYERS SQUIBB Total L-MYERS SQUIBB Total VE AL HEALTH Total COR ORTHO BIOTECH Total COR ORTHO BIOTECH Total	GENERAL.	5,100 391,330 501,500 700 700 700,769	51,000	4,589		13,396
L-MYERS SQUIBB Total VE Total AL HEALTH Total COR ORTHO BIOTECH Total	NATIONS	391,330 501,500 700 70,769	51,000	2,631	1,695	
L-MYERS SQUIBB Total VE VE VE VE VE VE VE VAL HEALTH VAL HEALTH COR ORTHO BIOTECH COR ORTHO BIOTE	NATIONS	501,500 700 70,769	000	155,200	175,000	772,530
L-MYERS SQUIBB Total NE Total IAL HEALTH TOTAL COR ORTHO BIOTECH C	NATIONS	70,769	203,000	200,000	12,500	917,000
L-MYERS SQUIBB Total NE NE NE NAL HEALTH SAL HEALTH Total COR ORTHO BIOTECH Total	NATIONS	69/'0/		16,300	1,300	18,300
L-MYERS SQUIBB Total VE Total IAL HEALTH COR ORTHO BIOTECH COR ORTHO BIOTECH Total		000 000	111,424	43,024	244 202	1 007 230
VE VE Total AL HEALTH AL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total		968,389	368,394	417,150	797'177	1,88,1
NE Total AL HEALTH AL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total		200	700	5,700	750	7,850
VE Total IAL HEALTH COR ORTHO BIOTECH Total	NATIONS				25,000	25,000
IAL HEALTH IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total		200	200	2,700	25,750	32,850
IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total	SENEDAL	1 439	8.463	6.052	5.443	21.398
AL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total	RESTRICTIONS				30	30
IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total	ON PROGRAMS	1000			25,000	25,000
IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total		750	200			1,450
IAL HEALTH Total COR ORTHO BIOTECH COR ORTHO BIOTECH Total	NATIONS	74,921	118,482	89,014	76,683	358,088
COR ORTHO BIOTECH Total		17,110	127,645	99),08	961,101	400,977
COR ORTHO BIOTECH Total		1,700			1,500	3,200
COR ORTHO BIOTECH Total	NATIONS				30,000	30,000
Total		1,700			31,500	33,200
Total	SENEDA		150			150
	SCH SCH	75				75
	NATIONS	28,385	6,750	675	90	35,890
		28,460	006'9	675	80	36,115
	0,000		2000	0.460	007 37	020 20
CITICORP UNRESTRICTED DONATIONS	NATIONS	5,863	8,773	9,133	10,108	006,10
CNA BREAST CANCER - GENERAL	GENERAL	2.446	4,855	5,259	2,483	15,053
OTHER PROGRAM RESTRICTIONS	RESTRICTIONS			2,500		2,500
	NATIONS	30,528	25,215	23,699	34,301	113,742
CNA Total		32,974	30,070	31,458	36,794	131,285
	T COLUMN		500	1077	B 030	12 951
COVIDIEN HODE I ONCER - GENERAL	GENERAL		8	176'4	360	360

THE PROPERTY OF THE PROPERTY O	- 地震学生	2008	200100	20000	T STANTAGE OF	OU OC
	PALIENI SERVICES			10,000	2000	
	INDESTRICTED DONATIONS	10000	200	701 45	32 341	68 948
COMPLEN Teles	CINCES INCIED DOING IONS	00000	200	38 529	50 946	100 475
CONDIENTOR		200'21	200	200,000		
EASTMAN KODAK	GEOGRAPHIC	75,000				75,000
ELI LILLY AND COMPANY	BREAST CANCER - GENERAL	820	3,185	2,554	950	7,549
	CAMPS FOR CHILDREN WITH CANCER	40.00	000	25	277.0	25
	HOPE LODGE	15,745	000'6	906'01	3,110	24,107
	PALIENT SERVICES	000'L	00/1	3	200	4,100
	SCIENTIFIC RESEARCH		92	2500	000	6000
	LINESTRICTED DONATIONS	61 537	81 112	76.580	78 599	297.828
ELI LILLY AND COMPANY Total		79,134	91.142	93,265	86.464	350,005
EMD SERONO	BREAST CANCER - GENERAL	5,025	30,000	46,310	15,000	96,335
	SCIENTIFIC RESEARCH			140,000		140,000
	UNRESTRICTED DONATIONS	1,650	25,000	104,100	126,183	256,913
EMD SERONO Total		6,675	25,000	290,410	141,163	483,248
ENDO PHARMACELTICALS	BREAST CANCER - GENERAL		30			30
	HOPE LODGE	2 2 2 2 2		25,000	1000	25,000
	OTHER PROGRAM RESTRICTIONS	2,500			200	3,000
	UNRESTRICTED DONATIONS	900'5	100	2,675	2,025	9,800
ENDO PHARMACEUTICALS Total		7,500	130	27,675	2,525	37,830
	DECEMBER OFFICER	0000	7 200	277.0	30	14 260
TAKM BUKEAU	DATIENT SEDVICES	200,5	200'4	2002	3	700
	UNRESTRICTED DONATIONS	89,380	76,940	73,639	89,847	329,805
FARM BUREAU Total		92,380	81,500	81,114	89,872	344,865
	Control of the Contro					
FIDELITY INVESTMENTS	BREAST CANCER - GENERAL			200		200
	CAMPS FOR CHILDREN WITH CANCER		50	B		100
	HOPETODGE		0009	100		6,100
	SCIENTIFIC RESEARCH		50			50
	UNRESTRICTED DONATIONS	060'89	33,650	61,125	8,550	171,415
FIDELITY INVESTMENTS Total		060'89	39,800	61,525	8,550	177,965
GE HEALTHCARE	GEOGRAPHIC	21,000	50.000	40,000		111,000
	UNRESTRICTED DONATIONS	14,050	20,000	26,000	5,260	65,310
GE HEALTHCARE Total		35,050	70,000	96,000	5,280	176,310
GENENTECH	BREAST CANCER - GENERAL	461	2 220	22.877	29.875	55,533
	OTHER PROGRAM RESTRICTIONS	1,121	150		500,000	501,271
	PATIENT SERVICES	3,000		6,700	5,700	15,400
	SCIENTIFIC RESEARCH	55,000	0,000	2000	107 00	55,000
	UNRESTRICTED DONATIONS	45,753	465,010	109,14/	88,485	C85,807
GENERALECT LOTAI		000'001	407,300	130,024	000'470	880'000'
GLAXOSMITHKLINE	BREAST CANCER - GENERAL	31,012	23,776	23,755	5,825	84,368
	CAMPS FOR CHILDREN WITH CANCER	900	200	200		1,500
	GEOGRAPHIC	1,086	2,000	1,106	1,500	10,692
	HOPELODGE	300,100	000'67	480		325,580
	DATIENT SEDVICES	18,000	000'6	10,000	2002	33,000
	SCIENTIEL RESEARCH	99	Ī	3	8	200
	UNRESTRICTED DONATIONS	264,687	162,128	126,793	323,984	877,592
GLAXOSMITHKLINE Total		617,135	223,404	163,334	332,009	1,335,882

COMPANYNAME	DONATION RESTRICTION	2006	Gift Calendar Year	7 Year 2008	2008	Grand Total
HEALTH ALLIANCE MEDICAL PLANS	BREAST CANCER - GENERAL			1,500	1,500	3,000
LEALTH ALLIANCE MEDICAL DI ANS Total	UNRESTRICTED DONATIONS	15,095	17,619	20,000	19,300	73.514
MENT ALLIANCE MEDICAL PLANS LOCAL		200,00	200	200	200	
HEALTH CARE SERVICE CORPORATION	BREAST CANCER - GENERAL	20	10,000	22,735	9,500	42,255
HEALTH CARE SERVICE CORPORATION Total	UNRESTRICTED DONATIONS	50,225	55.171	148,410	39,950	303,276
HEALTH NET	UNRESTRICTED DONATIONS	10,340	8,900	2,420	1,289	22,949
HENRY SCHEIN	HOPE LODGE				100,000	100,000
Ciec	BDCACT CANCED CENEDA!	A 790	8 500	034	387	12 557
	HOPE LODGE	350,000	150,000	26	50,000	550,000
	UNRESTRICTED DONATIONS	1,533	2,623	4,155	20,000	28,311
HOLOGIC Total		356,272	159,123	5,086	70,387	590,868
HOSPIRA	BREAST CANCER - GENERAL		39	116	286	440
	OTHER PROGRAM RESTRICTIONS			13	79	85
	PATIENT NAVIGATION PROGRAMS		15,000	15,000		30,000
	LINDESTRICTED DONATIONS	20 688	45,450	40 549	36 988	143 675
HOSPIRA Total		20,688	65,489	55,678	37,352	179,207
	Transfer and the second	OOL		0000		092.0
HUMANA	BREAST CANCER - GENERAL	2000		2,000		10,000
	HOPE LODGE	1,000		2000		1,000
	UNRESTRICTED DONATIONS	41,953	38,926	24,530	26,794	132,203
HUMANA Total		48,653	38,926	31,590	28,794	145,963
IDEC PHARMACEUTICAL	SCIENTIFIC RESEARCH	90,000				50,000
	The second secon					
JOHNSON & JOHNSON	BREAST CANCER - GENERAL	33,687	32,841	46,718	31,175	144,421
	HODE LODGE	700	0009	10.000	238.000	254,000
	OTHER PROGRAM RESTRICTIONS	26	90			106
	PATIENT SERVICES	200				200
	SCIENTIFIC RESEARCH	400	250	300	000 000	1,250
	TOBACCO CONTROL	281 710	306,826	262,231	304.839	1,135,606
JOHNSON & JOHNSON Total		296,253	376,267	682,899	674,014	2,032,433
KAISEB FOLINDATION	BREAST CANCEB - GENERAL	10 000	15.488	25,919		51.407
	CAMPS FOR CHILDREN WITH CANCER			1,000	1,000	2,000
	OTHER PROGRAM RESTRICTIONS	2,000	13,300		3,500	21,800
	PATIENT NAVIGATION PROGRAMS			20,000	20,000	100,000
	LINRESTRICTED DONATIONS	67 724	61.894	80.857	44.850	235,126
KAISER FOUNDATION Total		82,724	90,682	137,577	109,350	420,333
VALORIO DI DI LA PARTICIA DI CARROLLO DI C	S CHAPAC TOATION				2000	2000
NAISER PERMANENI E	CAMPS FOR CHILDREN WITH CANCER			İ	2,000	2,000
	NUTRITION & PHYSICAL ACTIVITY PROGRAMS	200,000				500,000
	PATIENT SERVICES	10 875	5.417	1 550	25,000	25,000
KAISER PERMANENTE Total		510,875	5,417	1,550	40,452	558,294
I INCORTY WITH IN INSTIDANCE COMPANY	PDEAST CANCED - CENEDAL	1 855	008	4 413	2 414	9 482
	HOPE LODGE	2001	3	7,788	1,836	9,604
	UNRESTRICTED DONATIONS	7,435	13,876	56,310	49,738	127,359
LIBERTY MITTIN INCIDENCE COMBANY Total		9,290	14,676	68.491	53,988	146 445

この「子本人」となることには、これが、これには、これには、これには、これには、これには、これには、これには、これには	CONTRACTOR RESINCTION STATEMENT OF THE S	2006	2007	2006		Grand Jobal
MADSH & MCI ENNAN COMBANIES	RDEACT CANCED . GENERAL	5,000		8 425	2.450	16.875
MAKSH & MCLENNAN COMPANIES	LINDESTRICTED DONATIONS	056		3300	20	4 300
MARSH & MCLENNAN COMPANIES Total		5,950		12,725	2,500	21,175
MCKESSON CORPORATION	BREAST CANCER - GENERAL		575	750	- 5	1,325
	GEOGRAPHIC OTHER PROGRAM RESTRICTIONS	1		1,500	1	1,500
Constitution from the Constitution of the Cons	UNRESTRICTED DONATIONS	22,668	16,407	9,129	11,700	59,904
MCKESSON CORPORATION Total		22,668	16,982	18,879	11,700	70,229
MCKESSON FOUNDATION	BREAST CANCER - GENERAL	009	525			1,125
MOKESSON EOI INDATION Total	UNRESTRICTED DONATIONS	2,250	7.100	12,175	11,747	33,272
MONEGOON TOOMON TOWN		7,990	070'/	12,173	14,141	and the
MEDTRONIC, INC.	BREAST CANCER - GENERAL			200		200
	OTHER PROGRAM RESTRICTIONS			0000	1,000	1,000
	SCIENTIFIC RESEARCH		1500	oon'e	8	1.500
	UNRESTRICTED DONATIONS	440	675	3,000	10,300	14,415
MEDTRONIC, INC. Total		440	2,175	8,200	12,000	22,815
MERCK & CO	BREAST CANCER - GENERAL	15.561	44 931	13.009	10.041	83.541
	GEOGRAPHIC	258,870		7,167	88,500	354,537
	HOPE LODGE	16,000	1,800	13,000	4,500	35,300
	PATIENT SERVICES	700	200	700	1,200	3,300
	SCIENTIFIC RESEARCH	20 724	106.950	100 448	88 253	373 387
MERCK & CO Total		371,365	156,882	134,324	190,493	853,065
					0.2.0	200 20
METROPOLITAN LIFE INSURANCE COMPANY	CANCER DEEVENTION & FABI Y DETECTION	1,000,000	9,108	7,560	3,770	1 000 000
	UNRESTRICTED DONATIONS	274,135	31,910	37,698	8,900	352,643
METROPOLITAN LIFE INSURANCE COMPANY Total		1,285,889	41,018	40,258	12,670	1,379,845
MGI PHARMACEUTICAL	BREAST CANCER - GENERAL		10,000			10,000
	PATIENT SERVICES	1,700	003.5	900		1,700
MGI PHARMACRI TICAL Total	UNKESTRICIED DONATIONS	0820	15,500	2009		25,550
MILLIPORE	BREAST CANCER - GENERAL	917	1,135	2,470	515	5,037
	HOPE LODGE LINRESTRICTED DONATIONS	1.745	7,835	6.287	8,431	24,078
MILLIPORE Total		2,662	8,770	11,237	8,946	31,615
NEW YORK LIFE INSURANCE COMPANY	BREAST CANCER - GENERAL	950	4,495	748	1,780	7,973
	CAMPS FOR CHILDREN WITH CANCER		30		25,000	25,000
	SCIENTIFIC RESEARCH	22 533	19 783	18 496	16.441	77 232
NEW YORK LIFE INSURANCE COMPANY Total	OWNEST WICHED DOWN TOWN	23,483	24,323	19,244	43,221	110,270
NORTHWESTERN MITH TALL FOLINDATION	GEOGRAPHIC			15.000		15,000
	SCIENTIFIC RESEARCH		15,000			15,000
ACCUMING THE INTERIOR FOR INDIVIDUAL COLUMN AND AND AND AND AND AND AND AND AND AN	UNRESTRICTED DONATIONS	900	2,000	1,000	18,000	21,500
NOR INVESTIGATION ISSUED		8	200,11	200'01	200,01	20010
NOVARTIS	BREAST CANCER - GENERAL	2,500	3,175	8,103	5,064	18,842
	CANCER PREVENTION & EARLY DETECTION	1,170,000	7007	638,565	92,000	1,900,565
	LINRESTRICTED DONATIONS	69.961	230.080	485.283	52.283	847.627
	CHARGING TO CONTINUE	100,00	200,000	000	200	1

COMPANY NAME	DONATION RESTRICTION	2006	Gift Calendar Year	lar Year 2008 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	2008	Grand Total
ONYX PHARMACEUTICALS	BREAST CANCER - GENERAL PATIENT NAVIGATION PROGRAMS PATIENT SERVICES	000,1	700	1,700	5,320	5,320
ONYX PHARMACEUTICALS Total	ONATES INICIED DONALIONS	2,000	2,250	5,200	11,320	20,770
OSI FOUNDATION	CAMPS FOR CHILDREN WITH CANCER UNRESTRICTED DONATIONS	5,000	40,000	25,000	55,000	65,000
OSI FOUNDATION Total		2,000	45,000	30,000	92,000	135,000
OSI PHARMACEUTICALS	INDESTRICTED DOMATIONS	700	5,000	5,000	5,000	15,700
OSI PHARMACEUTICALS Total	OWAGES INICITED DOING TOURS	5,332	16,000	13,953	11,500	46,785
OTHER PHARMACEUTICAL, MEDICAL DEVICE COMPANIES, FOUNDATIONS, AND INSURANCE COMPANIES	BREAST CANCER - GENERAL GEOGRAPHIC	19,334	3,536	13,465	6,379	42,714
	HOPE LODGE OTHER PROGRAM RESTRICTIONS PATIENT SERVICES	18.850	5400	500	21,800	2,750
	SCIENTIFIC RESEARCH UNRESTRICTED DONATIONS	67,957	81,983	85,837	87,026	332,902
OTHER PHARMACEUTICAL, MEDICAL DEVICE COMPANIES, FOUNDATIONS, AND INSURANCE COMPANIES Total		106,141	104,419	120,502	130,256	461,317
OWENS & MINOR	UNRESTRICTED DONATIONS	2,000	5,000	10,000	2,000	22,000
PACIFIC LIFE INSURANCE COMPANY	PATIENT SERVICES UNRESTRICTED DONATIONS	10,000	10,000	10,000	10,000	38,800
PACIFIC LIFE INSURANCE COMPANY Total		18,200	20,200	20,200	20,200	78,800
PACIFICARE PACIFICARE Total	PATIENT NAVIGATION PROGRAMS UNRESTRICTED DONATIONS	20,000 25,700 45,700			3,300	20,000 29,000 49,000
PFIZER	BREAST CANCER - GENERAL	31,763	31,766	33,723	10,156	107,408
	CAMPS FOR CHILDREN WITH CANCER CANCER PREVENTION & EARLY DETECTION GEOGRAPHIC	20,567	100,000	50,000	373,000	523,000 82,275
	HOPE LODGE OTHER PROGRAM RESTRICTIONS	12,094	20,600	7,005	37,661	57,220
	PATIENT NAVIGATION PROGRAMS PATIENT SERVICES	9,000	10,050	3,200	700	130,000
	SCIENTIFIC RESEARCH TOBACCO CONTROL TOBACCTOR ON TRANS	6,150	160,000	30,000	101,296	291,296
PFIZER Total	ONAESTROIED DOWNTONS	315,729	481,617	516,667	660,671	1,974,683
PFIZER FOUNDATION	BREAST CANCER - GENERAL	000	000	000 344	1,234	1,234
	GEOGRAPHIC	900,008	450,000	300,000	575,000	1,325,000
	HOPE LODGE TUBBACCO TUBBACCO TUBBACCO		275,000	325,300	250,000	850,300
PFIZER FOUNDATION Total	UNKEST KICLED DOWN HOMS	800,000	1,575,000	1,400,300	833,362	4,608,652
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA	BREAST CANCER - GENERAL	1,400				1,400
	GEOGRAPHIC	325,055			7,500	7,500
	UNRESTRICTED DONATIONS	53,319		277,500	11,000	341,819

	DONATION RESTRICTION	2006	Giff Calendar Yea	800	2008	Grand Total
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Total		379,774		277,500	18,500	675,774
PRUDENTIAL FINANCIAL	BREAST CANCER - GENERAL		24	310	003 0	334
	GEOGRAPHIC UNRESTRICTED DONATIONS	33,220	33,342	18,536	2,421	87,519
PRUDENTIAL FINANCIAL Total		33,220	36,886	21,346	4,921	96,353
PURDUE PHARMACEUTICAL	BREAST CANCER - GENERAL HOPE I ODGE	2,000	8,500	12,620	11,000	34,120
PURDUE PHARMACEUTICAL Total	OTHER PROGRAM RESTRICTIONS UNRESTRICTED DONATIONS	19,000	1,000 3,250 12,750	95,000 10,000 117,620	13,000	106,000 45,250 185,470
QUEST DIAGNOSTICS	BREAST CANCER - GENERAL CANCER PREVENTION & FARLY DETECTION	50,794	30,435	18,492	4,777	104,498
	GEOGRAPHIC HOPE LODGE			302		302
	OTHER PROGRAM RESTRICTIONS SCIENTIFIC RESEARCH	405	25	434		839
QUEST DIAGNOSTICS Total	UNRESTRICTED DONATIONS	446,355	249,238	71,115	49,187	867,142
ROCHE	BREAST CANCER - GENERAL	75	790	438,748	755,645	1,195,258
	GEOGRAPHIC	149,845	750	67,500		208,095
	OTHER PROGRAM RESTRICTIONS	00014		000	2,000	5,000
	SCIENTIFIC RESEARCH	06/	1,500	300	225	325
ROCHE Total	UNRESTRICTED DONATIONS	51,325	37,419	7,525	12,975	1,524,272
	DOLLACT CANOCID OFNICOAL		44 050	2000		16.050
SANOFI-AVENTIS	CANCER PREVENTION & EARLY DETECTION		000'11	2000	3,000	3,000
	GEOGRAPHIC	1,080,467	3,196	31,000	29.000	1,114,663
	OTHER PROGRAM RESTRICTIONS		200		200	1,000
	PATIENT NAVIGATION PROGRAMS PATIENT SERVICES	5,000	151,400	8,700	8,450	173,550
SANOFI-AVENTIS Total	UNRESTRICTED DONATIONS	1,238,142	377,896	18,300	40,500	1,921,488
	BOCAST CANCED CENEDAL			420	125	545
SOTENIA TEODOT	GEOGRAPHIC	10,524	8,711		7,450	26,685
	HOPE LODGE	3,000	1,000		12,500	1,000
	PATIENT SERVICES	700	700	700	200	2,800
	SCIENTIFIC RESEARCH UNRESTRICTED DONATIONS	52,130	34,572	26,728	10,921	124,350
SCHERING PLOUGH Total		66,354	45,962	27,848	31,818	172,002
SIGNAL PHARMACEUTICAL	BREAST CANCER - GENERAL	5,000	10,000	2,000	10,000	27,000
SIGNAL PHARMACEUTICAL Total	ONNEST INCIED DONALIGIS	31,000	30,000	20,000	20,000	101,000
SOUTHERN HEALTH SERVICES	UNRESTRICTED DONATIONS	5,000	2,000	5,800	5,400	21,200
STATE FARM	BREAST CANCER - GENERAL	1,294	75	225	20	1,644
	CAMPS FOR CHILDREN WITH CANCER		200	900		200
	PATIENT NAVIGATION PROGRAMS				200	200
	PATIENT SERVICES		300			000

86,7271 86,482 131,813 88,346 87,777 132,383 88,346 87,777 132,383 88,346 87,777 132,383 88,347 86,482 15,700 10,000 5,330 1,570 10,000 70,000 5,300 1,570 10,000 70,000 5,700 10,000 70,000 5,700 10,000 70,000 5,700 11,200 25,000 5,700 25,000 10,000 11,200 10,000 11,200 10,000 11,200 11,200 11,202 2,760 2,2868 16,7486 29,688 24,180 65,481 28,489 24,180 65,481 28,489 24,180 65,481 28,489 24,180 65,481 28,489 24,180 65,481 28,489 24,180 65,481 28,489 24,180 65,481 1,500 10,000 60,281 72,100 59,300 60,281 72,100 50,300 60,281 72,100 50,300 60,281 72,100 50,300 60,281 72,100 50,300 60,281 72,100 50,300 60,281 72,100 72,100 60,281 72,100 72,100 60,281 72,100 72,100 60,281 72,100 72,100 60,281 72,100 72,100 60,281 72,100 72,100 60,281 72,100		100000000000000000000000000000000000000	PERSONAL SERVICES	Gift Calendar Yea	- Land	OF RESIDE BOOK DECISION	Grand Total State
MANY LIMITED CHANTONS 73,549 81,771 86,484 11,1348 1	COMPANY NAME OF SAME PROPERTY OF SAME SAME SAME SAME SAME SAME SAME SAME	THE STATE OF THE S	The state of the s	The state of the s	900		900
MATERIANCE CARRENAL 11,204 6,410 6,410 1,4200		UNRESTRICTED DONATIONS	72,303	87,271	86,482	131,813	377,869
The control of the	STATE FARM Total		73,597	88,346	87,707	132,363	382,013
MANATUMITED Team UNRESTRUCTED DAWATONE 13,146 4770 5,200 1,570 1	STBVCED	BREAST CANCER - GENERAL	11 204	6.191	6.615	5,000	29,010
1,14 1,15		UNRESTRICTED DONATIONS	1,960	4,700	5,330	1,570	13,560
MANY LANTED Trained DIRECTS CANCERS GREEN TO 0,000 5	STRYKER Total		13,164	10,891	11,945	6,570	42,570
PATRIET WINGSTON COUNTY ON THE PATRIET SHOWED WITH CONTROL TO THE PATRIET SHOWED WIT	TAKETA PLANTAGE OF THE PARTY OF THE PARTY IN THE PARTY OF	DDCAOT CANOED CENEDAL	900	280	9	825	1 055
PATIENT SERVICES TOTAL TOTAL STATES TOTAL S	JAKEDA PRAKMACEO IICAL COMPANT LIMITED	CAMOS ECO CHILDEN WITH CANCER	2	2000	3	240	5,000
MANAY LAMTED Total STEERING SERVICES Total STEERIN		PATIENT NAVIGATION PROGRAMS		10,000	5.000	2.500	17,500
STATE STAT		PATIENT SERVICES	700		700	5,700	7,100
NAMES TROTTED DOWNTONS 4,086 21,385 8,4277 54,478		SCIENTIFIC RESEARCH		1000	25,000		25,000
PREAST CANCER - GENERAL 1,000 1,000 1,000 1,000		UNRESTRICTED DONATIONS	4,065	21,355	6,227	45,653	77,300
CONTRICT CONTRICTORS CALIFORM	TAKEDA PHARMACEUTICAL COMPANY LIMITED Total		4,865	36,635	36,977	54,478	132,955
PATIENT SERVICES 1,200 1,201 1,001 1	TAP PHARMACELITICALS	BREAST CANCER - GENERAL	4.000	898	303		5,171
PATIENT TRUCTED DOWATIONS		OTHER PROGRAM RESTRICTIONS		200			900
Description		PATIENT NAVIGATION PROGRAMS			3,000		3,000
Total BREAST CANCER CENERAL 1,100 675 85.501 46,473 816		PATIENT SERVICES		1,250			1,250
STATE STANCE ST		UNRESTRICTED DONATIONS	53,585	35,501	45,473	98	134,645
Total BREAST CANCER - GENERAL 1,000 6178 6128 1,000	TAP PHARMACEUTICALS Total		57,585	38,119	48,775	98	144,565
Total Direction Current 1,000 675 6588 1582	TOTAL OF THE PARTY	DECACT CANICED OCNICOAL				11 071	11 071
1,100 1,10	LEVA PHARMACEUTICALS USA	LINDESTRICTED DONATIONS	1 000	875	525	15.927	18,127
BREAST CANCER - GENERAL 1,137 1,756 1,887 750	TEVA PHARMACEUTICALS USA Total		1,000	675	525	26,998	29,198
BREAST CANCER - GENERAL							
Common	THE CHUBB CORPORATION	BREAST CANCER - GENERAL	1,137	1,755	1,687	120	6,329
HOPE LODGE		CAMPS FOR CHILDREN WITH CANCER		250			250
HOPE LODGE		HOPELODGE	20 455	107 30	006,1	04 480	150 315
HOPE LODGE		UNRESTRICTED DONATIONS	03,130	67 406	20,499	24,100	176 304
HOPE LODGE	THE CHUBBE CORPORATION Total		767'60	00,400	000'87	24,930	100'01
SCIENTIFIC RESEARCH 3,000 3,000	THERMO FISHER SCIENTIFIC	HOPE LODGE			10,000	10,000	20,000
BREAST CANCER - GENERAL		SCIENTIFIC RESEARCH		A Comment	30,000		30,000
BREAST CANCER - GENERAL		UNRESTRICTED DONATIONS		3,824	1,150	3,100	8,074
STORING 1,100 1,100 1,100 2,186 1,18971 1,18981 1,19981 1,	THERMO FISHER SCIENTIFIC Total			3,824	41,150	13,100	58,074
S TOTAL STANCER - GENERAL 16,100 1,1		Trouble district sorting	1000	000 7	0.750	300.0	7 3 3 7
S TOTAL STANDED CONTRICTED CONTRI	TRAVELERS FOUNDATION	BREAST CANCER - GENERAL	16.335	14 528	18 971	8.098	57.931
S Total BREAST CANCER - GENERAL 18,814 60,281 72,100 50,000 11,250 5,000	TRAVELERS FOUNDATION Total		17,435	15,730	21,721	10,383	65,268
S TOTAL SET CANCER - GENERAL. S TOTAL STATEMENT OF STRICTED DONATIONS S TOTAL SET STRICTED DONATIONS S TOTAL SET STRICTED DONATIONS BREAST CANCER - GENERAL BRIENTINIA NAVIGATION PROGRAMS BATIENT SERVICES BAT							
STOIGN CANCER C	UNITED HEALTHCARE SERVICES	BREAST CANCER - GENERAL			7,500	11,250	18,750
STODIA		GEOGRAPHIC	18 814	RD 284	72 100	2000	210.495
BREAST CANCER - GENERAL	UNITED HEALTHCARE SERVICES Total		18,814	60,281	79,600	75,550	234,245
BREAST CANCER - GENERAL							
GEOGRAPHIC 113 10,000 10HE PROGRAM RESTRICTIONS 84 292 75,000 11 10,000 10,000 11 10,000 10,000 10,000 11 10,000 10,	WELLPOINT	BREAST CANCER - GENERAL	5,548	13,111	4,513	2,920	26,093
OTHER PROGRAM RESTRICTIONS		GEOGRAPHIC			10,000		10,000
PATIENT NAVIGATION PROGRAMS		HOPE LODGE	Va	200			376
SCIENTIFIC RESEARCH		PATIENT NAVIGATION PROGRAMS	5	101	75.000		75,000
UNRESTRICTED DONATIONS 75,732 74,253 91,819 82,569 81,814 82,569 81,814 81,		SCIENTIFIC RESEARCH	30	104	80	11	225
BREAST CANCER - GENERAL 81,385 87,873 181,412 85,500 BREAST CANCER - GENERAL 1,048 PATIENT NAVIGATION PROGRAMS 375,000 1,048 PATIENT SERVICES 5,094 UNRESTRICTED DONATIONS 5,094		UNRESTRICTED DONATIONS	75,732	74,253	91,819	82,569	324,373
BREAST CANCER - GENERAL 1,048 1,048 1,048	WELLPOINT Total		81,395	87,873	181,412	85,500	436,178
PATIENT NAVIGATION PROGRAMS 375,000 75,000 75,000 5,094	MOLIT EQUINDATION	REFAST CANCER GENERAL				1.048	1.048
PATIENT SERVICES 75,000 5,094		PATIENT NAVIGATION PROGRAMS			375,000		375,000
UNRESTRICTED DONATIONS 500 5,094 650,500 8,143		PATIENT SERVICES			75,000		75,000
450,500 6,143		UNRESTRICTED DONATIONS			200	5,094	5,594
	WELLPOINT FOUNDATION Total				450,500	6,143	456,643

			Gift Calendar Year	Ir Year		Total Control of the Control
COMPANY NAME	DONATION RESTRICTION	2006	2007	2008	2008	Grand Total
WELLS FARGO	BREAST CANCER - GENERAL	11,733	10,640	13,872	35,574	71,819
	CAMPS FOR CHILDREN WITH CANCER		400	1,000		1,400
	CANCER PREVENTION & EARLY DETECTION	92,000				25,000
	GEOGRAPHIC	1,500	12,500	8,000	10,000	38,000
	HOPE LODGE	15,150		20	12,000	27,200
	OTHER PROGRAM RESTRICTIONS	2,000	12,000	9,000	2,000	27,000
	PATIENT SERVICES			25,000	25,000	90,000
	SCIENTIFIC RESEARCH		300	100		400
	YOUTH CANCER SURVIVOR SCHOLARSHIPS	10,000	1,500		X	11,500
	UNRESTRICTED DONATIONS	949,200	632,167	518,929	496,966	2,597,263
WELLS FARGO Total		1,053,583	669,507	571,952	584,540	2,879,582
WELLS FARGO FOUNDATION	UNRESTRICTED DONATIONS			100	31,825	31,925
WEST PHARMACEUTICAL SERVICES	BREAST CANCER - GENERAL			2,533		2,533
	HOPE LODGE	122,557	51,586	1,000		175,143
	UNRESTRICTED DONATIONS	4,770	7,900	475		13,145
WEST PHARMACEUTICAL SERVICES Total		127,327	59,486	4,008		190,821
HEAVE	GEOGRAPHIC		10.000		2,000	12,000
	HOPE LODGE		10,000			10,000
	PATIENT SERVICES		700	200	200	2,100
	UNRESTRICTED DONATIONS	15,625	12,735	13,248	18,045	59,653
WYETH Total		15,625	33,435	13,948	20,745	83,753
The state of the s	以前の発生するのでは、主要で西班方があれていている。現在問題で	21,101,918	11,481,895	21,101,018	10,334,335	58,227,286